ライフサイエンスコーパス: levetiracetam

1 amotrigine) and without proapoptotic action (levetiracetam).

2 were 25 mg/kg for valproate and 40 mg/kg for levetiracetam.

3 this effect was stronger under the intake of levetiracetam.

4 Most WWE were taking lamotrigine and/or levetiracetam.

5 tic protein targeted by the antiseizure drug levetiracetam.

6 d to valproate and 254 randomly allocated to levetiracetam.

7 ission was superior with valproate than with levetiracetam.

8 gnancy, and baseline dose of lamotrigine and levetiracetam.

9 reference after treatment with phenytoin and levetiracetam.

10 nt total synthesis of the antiepileptic drug levetiracetam.

11 ontrol and tolerability with lamotrigine and levetiracetam.

12 e noninducing anticonvulsants lamotrigine or levetiracetam.

13 her patients were switched to lamotrigine or levetiracetam.

14 nteraction is associated with gabapentin and levetiracetam.

15 107 (42%) participants randomly assigned to levetiracetam.

16 at have received the anti-seizure medication Levetiracetam.

17 ric disorders associated with topiramate and levetiracetam.

18 motrigine, -0.20 (0.02) mug/L/mg (P < .001); levetiracetam, -0.06 (0.03) mug/L/mg (P = .01); oxcarbaz

19 Lamotrigine (2.31% in 4195 pregnancies) and levetiracetam (1.77% in 817 pregnancies) were associated

20 or lamotrigine, 0.77 (95% CI, 0.60-0.99) for levetiracetam, 1.40 (95% CI, 1.19-1.64) for valproic aci

21 or lamotrigine, 0.96 (95% CI, 0.80-1.15) for levetiracetam, 1.40 (95% CI, 1.23-1.59) for valproic aci

22 /L/mg to 6.85 mug/L/mg; P < .001), 36.8% for levetiracetam (11.33 mug/L/mg to 7.16 mug/L/mg; P < .001

23 rk (valproate: 793 offspring; lamotrigine or levetiracetam: 1157 offspring), 1416 in Norway, and 2355

24 llowed by a 4-week washout period, then oral levetiracetam, 125 mg, twice daily for 4 weeks.

25 175 (38%) patients were randomly assigned to levetiracetam, 142 (31%) to fosphenyltoin, and 145 (31%)

26 en (valproate: 930 offspring; lamotrigine or levetiracetam: 1425 offspring).

27 re enrolled and randomly assigned to receive levetiracetam (145 patients), fosphenytoin (118), or val

28 2.9%; 95% CI, 1.7%-5.0%), and 33 of 1325 for levetiracetam (2.5%; 95% CI, 1.8%-3.5%).

29 ed were lamotrigine 1.5 mg/kg twice per day, levetiracetam 20 mg/kg twice per day, and zonisamide 2.5

30 er a blocking dose of the antiepileptic drug levetiracetam (20 mg/kg).

31 e volunteers were rescanned with preinjected levetiracetam (20 mg/kg, intravenously).

32 th epilepsy with reading-induced seizures on levetiracetam (3,000 mg/day) continued to experience rea

33 ay (valproate: 169 offspring; lamotrigine or levetiracetam: 344 offspring), and found no increased ri

34 rk (valproate: 259 offspring; lamotrigine or levetiracetam: 389 offspring) and 513 in Norway (valproa

35 -generated randomisation schedule to receive levetiracetam (40 mg/kg over 5 min) or phenytoin (20 mg/

36 minutes occurred in 68 patients assigned to levetiracetam (47%; 95% credible interval, 39 to 55), 53

37 rigine 50 mg (morning) and 100 mg (evening), levetiracetam 500 mg twice per day, and zonisamide 100 m

38 tamethylene-linked levetiracetam-huprine and levetiracetam-(6-chloro)tacrine hybrids to hit amyloid,

39 identified as the specific binding site for levetiracetam, a second generation antiepileptic drug.

40 e most prescribed antiepileptic medications, levetiracetam, acts by binding a protein of uncertain mo

41 lamotrigine (AHR, 1.18; 95% CI, 0.95-1.47), levetiracetam (AHR, 1.28; 95% CI, 0.77-2.14), carbamazep

42 of 298 WWE (78%) were taking lamotrigine or levetiracetam alone or in combination.

43 Finally, we show that feeding levetiracetam, an anti-epileptic medication, to Abeta-ex

44 Pretreatment of neurons with levetiracetam, an FDA-approved anti-epileptic drug, enha

45 1.458) compared with 1.222 (1.110-1.283) for levetiracetam and 1.232 (1.112, 1.307) for zonisamide at

46 ticipants were randomly allocated to receive levetiracetam and 260 participants to receive valproate.

47 re being used in management of myoclonus are levetiracetam and gamma-hydroxybutyric acid.

48 modern treatment choices include valproate, levetiracetam and lacosamide.

49 other than valproic acid, the combination of levetiracetam and lamotrigine demonstrated a lower risk

50 r all epilepsy types, among first-line ASMs, levetiracetam and lamotrigine were superior to oxcarbaze

51 features of two common anti-epileptic drugs (levetiracetam and lamotrigine) in an integrated manner.

52 ; and the ESETT study compared fosphenytoin, levetiracetam and sodium valproate in adults and childre

53 We find that levetiracetam and UCB-J induce vestibule occlusion, a ha

54 ntenance doses were 500 mg twice per day for levetiracetam and valproate, and for children aged 5-12

55 Levetiracetam and zonisamide are licensed as monotherapy

56 ical effectiveness and cost-effectiveness of levetiracetam and zonisamide compared with lamotrigine i

57 s designed to assess non-inferiority of both levetiracetam and zonisamide to lamotrigine for the prim

58 mised, open-label, controlled trial compared levetiracetam and zonisamide with lamotrigine as first-l

59 ted and had available data: 152 allocated to levetiracetam, and 134 to phenytoin.

60 otrigine, 144 (44%) participants who started levetiracetam, and 146 (45%) participants who started zo

61 lation, 312 patients (57.5%) were prescribed levetiracetam, and 231 (42.5%) were prescribed lamotrigi

62 igine, 320 participants randomly assigned to levetiracetam, and 315 participants randomly assigned to

63 wn antiepileptic drugs such as ethosuximide, levetiracetam, and lacosamide.

64 epileptic drugs (AEDs) such as ethosuximide, levetiracetam, and lacosamide.

65 We studied the effects of Lamotrigine, Levetiracetam, and of a novel potassium channel opener (

66 xposure to AEDs (carbamazepine, lamotrigine, levetiracetam, and sodium valproate) was defined using r

67 Lamotrigine and levetiracetam are relatively safe.

68 recently been reawakened by the licensing of levetiracetam as a potentially major new antiepileptic d

69 s and study designs, are needed to establish levetiracetam as a treatment for schizophrenia.

70 ectiveness research study suggest the use of levetiracetam as initial alternative monotherapy in fema

71 ) or preblocking with the antiepileptic drug levetiracetam at 10 and 30 mg/kg.

72 n, treatment with the atypical antiepileptic levetiracetam at a low dose shown previously to improve

73 he drug molecules, such as Carbamazepine and Levetiracetam attached sulfonimidoyl fluorides are also

74 The antiepileptic drug, levetiracetam, blocked Kv4.2 depletion.

75 -homoalanine, which is a chiral precursor of levetiracetam, brivaracetam, and ethambutol.

76 nally exposed to valproate vs lamotrigine or levetiracetam, but no difference in CM risk was observed

77 nd lamotrigine are first-line therapy, while levetiracetam can be also considered if there is no hist

78 al exposure to monotherapy with lamotrigine, levetiracetam, carbamazepin, oxcarbazepine, gapapentin,

79 as designed to assess the non-inferiority of levetiracetam compared with valproate for the primary ou

80 ical effectiveness and cost-effectiveness of levetiracetam compared with valproate in participants wi

81 the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternativ

82 Overall, treatment with levetiracetam did not change NIH-EXAMINER composite scor

83 Levetiracetam did not meet the criteria for non-inferior

84 Levetiracetam did not meet the criteria for non-inferior

85 e antiseizure medications, valproic acid and levetiracetam, did not improve behavior or prevent neuro

86 osure to (1) valproate or (2) lamotrigine or levetiracetam during the spermatogenic risk window (deri

87 Patients treated with levetiracetam experienced adverse effects more frequentl

88 One participant who received levetiracetam followed by phenytoin died as a result of

89 ficacy outcome was met in those treated with levetiracetam for 52% (95% credible interval 41-62) of c

90 DESIGN, SETTING, AND PARTICIPANTS: The Levetiracetam for Alzheimer's Disease-Associated Network

91 red the efficacy and safety of phenytoin and levetiracetam for second-line management of paediatric c

92 of three intravenous anticonvulsive agents - levetiracetam, fosphenytoin, and valproate - in children

93 status epilepticus, the anticonvulsant drugs levetiracetam, fosphenytoin, and valproate each led to s

94 SETT) we compared the efficacy and safety of levetiracetam, fosphenytoin, and valproate in establishe

95 shed status epilepticus respond similarly to levetiracetam, fosphenytoin, and valproate, with treatme

96 (<18 years, 18-65 years, and >65 years), to levetiracetam, fosphenytoin, or valproate.

97 gher risk in the valproate vs lamotrigine or levetiracetam group (pooled adjusted HR, 1.50; 95% CI: 1

98 was 35 min (IQR 20 to not assessable) in the levetiracetam group and 45 min (24 to not assessable) in

99 was terminated in 106 (70%) children in the levetiracetam group and in 86 (64%) in the phenytoin gro

100 nytoin group and more deaths occurred in the levetiracetam group than in the other groups, but these

101 By using a low dose of the antiepileptic levetiracetam hippocampal activation in aMCI was reduced

102 sion was superior with lamotrigine than both levetiracetam (HR 1.32 [97.5% CI 1.05 to 1.66]) and zoni

103 SV2A is the target of the antiepileptic drug levetiracetam, human blocking studies have characterized

104 ynthesized a series of heptamethylene-linked levetiracetam-huprine and levetiracetam-(6-chloro)tacrin

105 The levetiracetam-huprine hybrid 10 significantly reduced th

106 c drugs (topiramate, lacosamide, pregabalin, levetiracetam), hypothermia, magnesium, pyridoxine, immu

107 e primary outcome, in prespecified analysis, levetiracetam improved performance on spatial memory and

108 2.5%) exposed to valproate vs lamotrigine or levetiracetam in Denmark, Norway, and Sweden, respective

109 Levetiracetam increased theta, beta and gamma power, whi

110 Levetiracetam is especially useful for posthypoxic myocl

111 Levetiracetam is increasingly prescribed for these patie

112 motrigine (LTG) 0.31 (-0.38 to 1.00) p=0.38; levetiracetam (LEV) 1.00 (0.16 to 1.84) p=0.02; sodium v

113 Brivaracetam (BRV) and levetiracetam (LEV) are antiseizure medications (ASMs);

114 Among the drugs tested, only levetiracetam (LEV) effectively reduced abnormal spike a

115 The antiepileptic drug levetiracetam (LEV) is a potential treatment for alcohol

116 Levetiracetam (LEV) is a prominent antiepileptic drug th

117 Critically ill patients eliminate levetiracetam (LEV) more rapidly than healthy controls,

118 We hypothesized that levetiracetam (LEV), a drug binding to the synaptic vesi

119 le protein SV2A is the brain binding site of levetiracetam (LEV), a new antiepileptic drug with a uni

120 ied as the binding site of the antiepileptic levetiracetam (LEV), making it an interesting therapeuti

121 The same analyses were performed with levetiracetam (LEV).

122 interneurons and suggest that the action of levetiracetam may be due largely to effects on a subset

123 Thus, levetiracetam might be part of a valuable new approach f

124 peridol (N = 8-15), xanomeline (N = 8-13) or levetiracetam (N = 6-15) and were subsequently tested fo

125 mly assigned to receive lamotrigine (n=330), levetiracetam (n=332), or zonisamide (n=328).

126 nown to have antipsychotic activity, but not levetiracetam, normalized the SRM behavior to control le

127 The Lassen plot was applied to compute levetiracetam occupancy and nondisplaceable distribution

128 ent failure (TF) among patients who received levetiracetam or lamotrigine as initial monotherapy.

129 Levetiracetam or lamotrigine as initial monotherapy.

130 Against Epilepsy criteria and who initiated levetiracetam or lamotrigine as initial monotherapy.

131 zepine or phenytoin to the noninducing drugs levetiracetam or lamotrigine produces rapid and clinical

132 cing neuronal excitability either by feeding Levetiracetam or silencing of neurons in the involved ci

133 e randomly allocated (1:1) to receive either levetiracetam or valproate, using a minimisation program

134 These findings do not support the use of levetiracetam or zonisamide as first-line treatments for

135 ed presence of Dilantin (phenytoin), Keppra (levetiracetam), or neither.

136 s post-SE, animals received sodium selenate, levetiracetam, or vehicle subcutaneousinfusion continuou

137 ent utilising factor to receive lamotrigine, levetiracetam, or zonisamide.

138 of MCMs was observed in offspring exposed to levetiracetam, oxcarbazepine, and lamotrigine.

139 g systematic with rescue TDM of lamotrigine, levetiracetam, oxcarbazepine, topiramate, brivaracetam,

140 This decrease in functioning was evident for levetiracetam (PE, -18.9 [95% CI, -26.8 to -10.9]; P < .

141 lex with FDA-approved antiseizure medication levetiracetam; PET imaging tracer UCB-J; experimental an

142 of TF compared with other combinations with levetiracetam plus other ASM (adjusted HR, 2.41; 95% CI,

143 Levetiracetam reduced the uptake of (18)F-SynVesT-1 in a

144 hieved similar rates of seizure freedom, but levetiracetam remained superior to lamotrigine and oxcar

145 e ASMs achieved similar seizure freedom, but levetiracetam remained superior to lamotrigine and oxcar

146 Preblocking with 10 and 30 mg/kg of levetiracetam resulted in approximately 60% and 90% occu

147 Flunarizine (RoM, 0.46; 95% CI, 0.26-0.81), levetiracetam (RoM, 0.47; 95% CI, 0.30-0.72), riboflavin

148 ), valproate (RoM, 0.60; 95% CI, 0.49-0.72), levetiracetam (RoM, 0.62; 95% CI, 0.50-0.77), and cinnar

149 es and comparative ease of administration of levetiracetam, suggest it could be an appropriate altern

150 Levetiracetam suppressed TRSP theta, alpha and beta powe

151 es appeared to be better for lamotrigine and levetiracetam than for phenytoin.

152 ents such as topiramate, disodium valproate, levetiracetam, the antihistamine cyproheptadine, and the

153 our drugs (warfarin, tacrolimus, digoxin and levetiracetam) through an ex vivo perfusion assay and th

154 trast, the new AEDs gabapentin, lamotrigine, levetiracetam, tiagabine, topiramate, vigabatrin, and zo

155 s: the EcLiPSE and ConSEPT studies, compared levetiracetam to phenytoin in children; and the ESETT st

156 ition of the SV2A-binding antiepileptic drug levetiracetam to the medium inhibited the galactose-depe

157 dent response over time, with phenobarbital, levetiracetam, topiramate and adrenocorticotropic hormon

158 ong participants with epileptiform activity, levetiracetam treatment improved performance on the Stro

159 The primary outcome was the ability of levetiracetam treatment to improve executive function (m

160 A priori selected study ASMs were levetiracetam, valproate, and phenytoin.

161 amazepine and greater use of lamotrigine and levetiracetam was associated with a 39% decline in preva

162 Levetiracetam was associated with a reduced risk of card

163 An IPTW-adjusted Cox model showed that levetiracetam was associated with a reduced risk of trea

164 t IGE syndromes, the higher effectiveness of levetiracetam was confirmed only in patients with juveni

165 Levetiracetam was discovered to have antiseizure activit

166 Levetiracetam was dominated by valproate in the cost-uti

167 Levetiracetam was found not to disrupt synaptic developm

168 Compared with valproate, levetiracetam was found to be neither clinically effecti

169 Although levetiracetam was not significantly superior to phenytoi

170 azepine for seizure freedom (P < 0.001), and levetiracetam was superior to lamotrigine and oxcarbazep

171 In this randomized clinical trial, levetiracetam was well tolerated and, although it did no

172 Brivaracetam, an analog of levetiracetam, was identified in a medicinal chemistry c

173 o either (1) valproate or (2) lamotrigine or levetiracetam were identified and followed-up until 12 y

174 iption of antiepileptic drugs, phenytoin and levetiracetam were prescribed most often.

175 d broad-spectrum ASMs, such as valproate and levetiracetam, were more effective for individuals with

176 HR, 2.38; 95% CI, 1.40-4.06) and exposure to levetiracetam with anxiety (aHR, 2.17; 95% CI, 1.26-3.72

177 The duotherapies levetiracetam with carbamazepine and lamotrigine with to

178 isorders in children of women with epilepsy: levetiracetam with carbamazepine: 8-year cumulative inci

179 No increased risk was associated with levetiracetam with lamotrigine (8-year cumulative incide

180 abel, randomised controlled trial to compare levetiracetam with valproate as first-line treatment for